Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon Jun 02, 2021 9:36am
152 Views
Post# 33309872

RE:RE:SOME Biogen chatter

RE:RE:SOME Biogen chatterAs FDA decides on Biogen drug for Alzheimer’s, patients and families hold out hope
By Jonathan Saltzman Globe Staff,Updated June 2, 2021, 52 minutes ago
 
Within days, federal regulators will decide whether to approve the first new drug for Alzheimer’s disease in nearly two decades, a controversial medicine from Cambridge-based Biogen that seems to have as many detractors as proponents.
It’s called aducanumab, and Kirsten Hano is among those hoping it wins approval.
A 1989 graduate of Williams College who lives in Wellesley, Hano once seemed able to do it all: work 10-hour days as an advertising executive; shepherd three sons to extracurricular activities; start a nonprofit group; and play ice hockey weekly with friends. But last November, after several years of finding it increasingly hard to complete routine tasks, she received a staggering diagnosis: early-onset Alzheimer’s.
 
 
 
https://www.bostonglobe.com/2021/06/02/business/fda-decides-biogen-drug-alzheimers-patients-families-hold-out-hope/

<< Previous
Bullboard Posts
Next >>